Karl R Clauser

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2899264/publications.pdf Version: 2024-02-01



KADI P CIALISED

#	Article	IF	CITATIONS
1	Proteogenomics connects somatic mutations to signalling in breast cancer. Nature, 2016, 534, 55-62.	27.8	1,384
2	Mass Spectrometry Profiling of HLA-Associated Peptidomes in Mono-allelic Cells Enables More Accurate Epitope Prediction. Immunity, 2017, 46, 315-326.	14.3	596
3	Integrated proteomic analysis of post-translational modifications by serial enrichment. Nature Methods, 2013, 10, 634-637.	19.0	534
4	Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma. Cell, 2020, 182, 200-225.e35.	28.9	410
5	Reproducible workflow for multiplexed deep-scale proteome and phosphoproteome analysis of tumor tissues by liquid chromatography–mass spectrometry. Nature Protocols, 2018, 13, 1632-1661.	12.0	377
6	A large peptidome dataset improves HLA class I epitope prediction across most of the human population. Nature Biotechnology, 2020, 38, 199-209.	17.5	324
7	Proteogenomic Characterization of Endometrial Carcinoma. Cell, 2020, 180, 729-748.e26.	28.9	296
8	Proteogenomic Landscape of Breast Cancer Tumorigenesis and Targeted Therapy. Cell, 2020, 183, 1436-1456.e31.	28.9	273
9	TMT Labeling for the Masses: A Robust and Cost-efficient, In-solution Labeling Approach. Molecular and Cellular Proteomics, 2019, 18, 1468-1478.	3.8	245
10	An Analysis of the Sensitivity of Proteogenomic Mapping of Somatic Mutations and Novel Splicing Events in Cancer. Molecular and Cellular Proteomics, 2016, 15, 1060-1071.	3.8	104
11	Profiling SARS-CoV-2 HLA-I peptidome reveals TÂcell epitopes from out-of-frame ORFs. Cell, 2021, 184, 3962-3980.e17.	28.9	98
12	Microscaled proteogenomic methods for precision oncology. Nature Communications, 2020, 11, 532.	12.8	78
13	Streamlined Protocol for Deep Proteomic Profiling of FAC-sorted Cells and Its Application to Freshly Isolated Murine Immune Cells*. Molecular and Cellular Proteomics, 2019, 18, 995a-1009.	3.8	69
14	MS-Based HLA-II Peptidomics Combined With Multiomics Will Aid the Development of Future Immunotherapies. Molecular and Cellular Proteomics, 2021, 20, 100116.	3.8	13